Evidence map›Paper›PMID 33236174›Full record

ArticleParasitology research2021

Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.

Fernanda Karoline Vieira da Silva Torchelsen, Thaila Martins Silva, Matheus Marques Milagre, Rafael Rodrigues Silva, Levi Eduardo Soares Reis, Renata Tupinambá Branquinho, Glenda Nicioli Silva, Marta de Lana

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fernanda Karoline Vieira da Silva TorchelsenPrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Thaila Martins SilvaDepartamento de Analises Clínicas, Escola de Farmácia, Universidade Federal de Ouro Preto (UFOP), Ouro Preto, Brazil.
Matheus Marques MilagrePrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Rafael Rodrigues SilvaPrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Levi Eduardo Soares ReisPrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Renata Tupinambá BranquinhoPrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Glenda Nicioli SilvaPrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil.
Marta de LanaPrograma de Pós-Graduação em Ciências Farmacêuticas (CiPHARMA), Universidade Federal de Ouro Preto (UFOP), Campus Universitário Morro do Cruzeiro, Ouro Preto, MG, 35400-000, Brazil. delana@edu.ufop.br.ORCID https://orcid.org/0000-0002-1565-4707
Universidade Federal de Ouro Preto · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico Process 431413/2016-9Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00766/16Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01160-15
6 · The paper itself

Abstract

Chagas disease (CD) is endemic in Latin America. Drugs available for its treatment are benznidazole (BZ)/nifurtimox (NF), both with low efficacy in the late infection and responsible for several side effects. Studies of new drugs for CD among natural products, and using drug combinations with BZ/NF are recommended. Silibinin (SLB) is a natural compound that inhibits the efflux pump (Pgp) of drugs in host cell membranes, causes death of trypanosomatids, has anti-inflammatory activity, and was never assayed against T. cruzi. Here, in vitro and in vivo activities of SLB, SLB+BZ, and BZ against T. cruzi Y strain were evaluated. Cytotoxicity of SLB in VERO cells by the MTT method revealed IC50 of 250.22 μM. The trypanocidal activity evaluated by resazurin method in epimastigotes showed that SLB 25 μM inhibited parasite growth. SLB IC50 and selectivity index (SI) for amastigote were 79.81 μM and 3.13, respectively. SLB100+BZ10 showed higher parasite inhibition (91.44%) than SLB or BZ. Swiss mice infected with Y strain were treated with SLB, SLB+BZ, and BZ. Parasitemia was evaluated daily and 90, 180, and 240 days after treatment in surviving animals by hemoculture, blood qPCR, and after euthanasia, by qPCR in heart tissue. SLB monotherapy was not able to control the parasitemia/mortality of the animals. Parasitological negativation of 85.7-100% was observed in the experimental groups treated with SLB+BZ. Although SLB had shown activity against T. cruzi in vitro, it was not active in mice. Thus, the results of the therapeutic effect observed with SLB+BZ may be interpreted as a result from BZ action.

Indexed as

AnimalsChagas DiseaseChlorocebus aethiopsFemaleHeartInhibitory Concentration 50MiceNitroimidazolesParasitemiaReal-Time Polymerase Chain ReactionSilybinTrypanocidal AgentsTrypanosoma cruziVero CellsbenzonidazoleNitroimidazolesSilybinTrypanocidal AgentsBenznidazoleDrug associationIn vitroIn vivoSilibininTrypanosoma cruzi

Identifiers

PMID33236174
OpenAlexW3109883487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.